ABSTRACT
BACKGROUND: Interstitial lung disease-associated antisynthetase syndrome (AS-ILD) carries significant morbidity and mortality. Corticosteroids and immunosuppressive drugs are the mainstay of treatment. Human immunoglobulin (IVIg), an immunomodulator without immunosuppressive properties, is effective in myositis but the evidence supporting its use in ILD is scarce. OBJECTIVE: To describe clinical outcomes of AS-ILD patients receiving IVIg. METHODS: Retrospective analysis of AS-ILD patients. Linear mixed models using restricted maximum likelihood estimation was used to estimate the change in lung function and corticosteroid dose over time. RESULTS: Data from 17 patients was analyzed. Median follow-up was 24.6 months. Fourteen patients had refractory disease. The mean percent-predicted forced vital capacity (FVC%) (pâ¯=â¯0.048) and percent-predicted diffusing capacity of the lung for carbon monoxide (DLCO%) (pâ¯=â¯0.0223) increased over time, while the mean prednisone dose (pâ¯<â¯0.001) decreased over time. Seven patients achieved a >10% increase in FVC%, including two who used IVIg as initial treatment. Five patients showed a >10% increase in DLCO% and TLC%. Nine (53%) patients experienced side effects. CONCLUSIONS: IVIg may be a useful complementary therapy in active progressive AS-ILD but is associated with potential side effects. Fssssurther investigation is required to determine the value of IVIg as an initial treatment in AS-ILD.
Subject(s)
Immunoglobulins, Intravenous/therapeutic use , Immunologic Factors/therapeutic use , Lung Diseases, Interstitial/therapy , Myositis/therapy , Administration, Intravenous , Adrenal Cortex Hormones/therapeutic use , Adult , Aged , Carbon Monoxide/metabolism , Female , Follow-Up Studies , Humans , Immunoglobulins, Intravenous/adverse effects , Immunosuppressive Agents/therapeutic use , Lung/physiopathology , Lung Diseases, Interstitial/complications , Lung Diseases, Interstitial/mortality , Male , Middle Aged , Myositis/complications , Myositis/mortality , Prednisone/therapeutic use , Pulmonary Diffusing Capacity/drug effects , Retrospective Studies , Treatment Outcome , Vital Capacity/drug effectsSubject(s)
Acute Chest Syndrome/etiology , Hemoglobin SC Disease/complications , Muscle Weakness/etiology , Myositis/diagnosis , Acute Chest Syndrome/diagnosis , Adult , Diagnosis, Differential , Dyspnea/etiology , Female , Humans , Magnetic Resonance Imaging , Myalgia/etiology , Tomography, X-Ray ComputedABSTRACT
This study was undertaken to evaluate the effect of a cyclooxygenase inhibitor, ibuprofen, at various time intervals in a live Escherichia coli model of canine septic shock. Group I (control) animals (n = 5) received a LD100 dose of 10(9) live E. coli per kilogram were given no further treatment. Group II animals (n = 5) received a 10 mg/kg bolus of ibuprofen 10 min prior to bacterial infusion. Group III animals (n = 5) received ibuprofen 15 min after the bacterial infusion. Statistical analysis revealed the following: Group II animals had significantly higher MABP and significantly lower levels of serum fluorescent products (superoxide radical activity), plasma thromboxane B2, prostaglandin E2, and endotoxin levels compared to Group I animals (P less than 0.05). Plasma levels of tumor necrosis factor (TNF) and interleukin-6 (IL-6) were significantly elevated (P less than 0.05) from baseline in all animals (Groups I, II, and III), but ibuprofen treatment failed to either increase or decrease these levels. This study demonstrates that ibuprofen treatment can significantly reverse the deleterious hemodynamic and metabolic effects commonly seen in live E. coli septic shock without depressing the endogenous production of TNF or IL-6. These data support the hypothesis that sepsis initiates a cascade of mediators with the cytokines TNF and IL-6 being proximal events which in turn stimulate the next level, with ibuprofen probably exerting its inhibitory effect distal to this point in the cascade.
